UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2016-11, Vol.375 (19), p.1856-1867

2016

Volltextzugriff (PDF)

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Annals of oncology, 2018-04, Vol.29 (4), p.959-965

2018

Volltextzugriff (PDF)

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-10, Vol.373 (17), p.1627-1639

2015

Volltextzugriff (PDF)

“Timing is Everything”: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma

Annals of oncology, 2023-03, Vol.34 (3), p.213-214

2023

Volltextzugriff (PDF)

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

Clinical cancer research, 2015-02, Vol.21 (3), p.632-641

2015

Volltextzugriff (PDF)

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Annals of oncology, 2019-02, Vol.30 (2), p.297-302

2019

Volltextzugriff (PDF)

Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer

Annals of oncology, 2016-04, Vol.27 (4), p.590-599

2016

Volltextzugriff (PDF)

Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology

Nature communications, 2022-11, Vol.13 (1), p.6572-14, Article 6572

2022

Volltextzugriff (PDF)

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

Journal of clinical oncology, 2011-08, Vol.29 (23), p.3120-3125

2011

Volltextzugriff (PDF)

New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1029-1038

2013

Volltextzugriff (PDF)

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

Clinical cancer research, 2015-02, Vol.21 (4), p.870-881

2015

Volltextzugriff (PDF)

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Journal of clinical oncology, 2008-11, Vol.26 (31), p.5043-5051

2008

Volltextzugriff (PDF)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Volltextzugriff (PDF)

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Journal of clinical oncology, 2004-01, Vol.22 (1), p.77-85

2004

Volltextzugriff (PDF)

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Scientific reports, 2021-10, Vol.11 (1), p.20059-20059, Article 20059

2021

Volltextzugriff (PDF)

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

Clinical cancer research, 2015-12, Vol.21 (24), p.5439-5444

2015

Volltextzugriff (PDF)

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2063-2069

2012

Volltextzugriff (PDF)

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

Journal of clinical oncology, 2004-04, Vol.22 (8), p.1382-1388

2004

Volltextzugriff (PDF)

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5578-5587

2005

Volltextzugriff (PDF)

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-01, Vol.28 (1), p.56-62

2010

Volltextzugriff (PDF)

Induction Chemotherapy for Head and Neck Cancer: Recent Data

The oncologist (Dayton, Ohio), 2010-10, Vol.15 (S3), p.3-7

Vokes, Everett E.

2010

Volltextzugriff (PDF)

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer

Annals of oncology, 2023-08, Vol.34 (8), p.714-722

2023

Volltextzugriff (PDF)

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Journal of clinical oncology, 2008-10, Vol.26 (29), p.4708-4713

2008

Volltextzugriff (PDF)

1 – 25 von 1.276

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.170)
Mit Volltextzugriff
(1.060)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(611)
Humans
(603)
Life Sciences & Biomedicine
(580)
Oncology
(483)
Female
(353)
Male
(351)
Middle Aged
(329)
Biological And Medical Sciences
(312)
Aged
(311)
Medical Sciences
(308)
Adult
(275)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(220)
Combined Modality Therapy
(173)
Pharmacology. Drug Treatments
(168)
Antineoplastic Agents
(155)
Chemotherapy
(152)
Lung Neoplasms - Drug Therapy
(152)
Tumors
(152)
Head And Neck Neoplasms - Drug Therapy
(146)
Treatment Outcome
(135)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

“Timing is Everything”: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer

Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Induction Chemotherapy for Head and Neck Cancer: Recent Data

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Suchergebnisse filtern